How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Personalized Cell Therapeutic Market
- By Therapy Type: Chimeric Antigen Receptor T-cell (CAR-T) Therapy, T-cell Receptor (TCR) Therapy, Tumor-Infiltrating Lymphocytes (TIL) Therapy, Dendritic Cell Therapy, Natural Killer (NK) Cell Therapy
- By Cell Source: Autologous Cell Therapy, Allogeneic Cell Therapy
- By Indication: Hematologic Malignancies, Solid Tumors, Autoimmune Diseases, Infectious Diseases
- By Manufacturing Process: Ex Vivo Cell Expansion, Gene Editing and Modification, Cryopreservation and Storage
- By End User: Hospitals and Clinics, Specialized Cell Therapy Centers, Research and Academic Institutes
Top segment
Chimeric Antigen Receptor T-cell (CAR-T) Therapy XX% share · $X,XXXM
In the full report →
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Chimeric Antigen Receptor T-cell (CAR-T) Therapy leads By Therapy Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 17 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 291 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.173 →
- 12 Company Profiles 17 players: SWOT & benchmarking p.181 →
Full report · locked preview
Everything inside the Personalized Cell Therapeutic Market report
A complete, evidence-based study - 12 chapters and 122 sections covering market size, segmentation across 5 axes, regional analysis and 17 company profiles, forecast to 2033.
Segmentation covered
Therapy Type 5
Cell Source 2
Indication 4
Manufacturing Process 3
End User 3
Companies profiled
Novartis AG
Gilead Sciences
Inc. (Kite Pharma)
Bristol-Myers Squibb (Celgene)
Adaptimmune Therapeutics plc
Bluebird Bio Inc.
Legend Biotech Corporation
Sangamo Therapeutics Inc.
Celyad Oncology SA
Autolus Therapeutics plc
Allogene Therapeutics Inc.
Poseida Therapeutics Inc.
+5 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
17 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Gilead Sciences
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Inc. (Kite Pharma)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Bristol-Myers Squibb (Celgene)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Adaptimmune Therapeutics plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Bluebird Bio Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Legend Biotech Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Sangamo Therapeutics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Celyad Oncology SA
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Autolus Therapeutics plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Allogene Therapeutics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Poseida Therapeutics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Immatics Biotechnologies GmbH
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →Atara Biotherapeutics Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Tmunity Therapeutics Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Fate Therapeutics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$10,441M by 2033 · 10.0% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Chimeric Antigen Receptor T-cell (CAR-T) Therapy27.7
- T-cell Receptor (TCR) Therapy16.6
- Tumor-Infiltrating Lymphocytes (TIL) Therapy20.7
- Dendritic Cell Therapy17.7
- Natural Killer (NK) Cell Therapy17.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,603M → $3,107M · 8.6%
Europe$1,117M → $2,464M · 10.4%
Asia Pacific$1,020M → $2,173M · 9.9%
Latin America$631.3M → $1,350M · 10.0%
Middle East and Africa$485.6M → $1,085M · 10.6%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.992026
10.012027
10.022028
10.022029
10.052030
10.062031
10.072032
10.082033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Novartis AG10.3
- Gilead Sciences20.6
- Inc. (Kite Pharma)14.5
- Bristol-Myers Squibb (Celgene)4.7
- Adaptimmune Therapeutics plc8.9
- Bluebird Bio Inc.13.1
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Therapy Type21.3%
Cell Source18.1%
Indication16.6%
Manufacturing Process19.0%
End User25.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America30.5
- Europe24.2
- Asia Pacific21.3
- Latin America13.3
- Middle East and Africa10.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Novartis AG | 78 | 79 | 92 | 78 | 80 | 84 | 82 |
| Gilead Sciences | 81 | 74 | 76 | 71 | 92 | 86 | 80 |
| Inc. (Kite Pharma) | 79 | 71 | 72 | 64 | 88 | 85 | 77 |
| Bristol-Myers Squibb (Celgene) | 75 | 75 | 61 | 80 | 80 | 77 | 75 |
| Adaptimmune Therapeutics plc | 59 | 70 | 61 | 71 | 60 | 71 | 65 |
| Bluebird Bio Inc. | 58 | 59 | 59 | 49 | 63 | 64 | 59 |
| Legend Biotech Corporation | 42 | 61 | 54 | 51 | 62 | 53 | 54 |
| Sangamo Therapeutics Inc. | 56 | 49 | 54 | 52 | 36 | 54 | 50 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Novartis AG
- Gilead Sciences
- Inc. (Kite Pharma)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Novartis AG | ◐ | ◐ | ✓ | ✓ | ◐ | ◐ |
| Gilead Sciences | ◐ | ✓ | ✓ | − | ✓ | ✓ |
| Inc. (Kite Pharma) | ✓ | − | ◐ | ◐ | ✓ | ◐ |
| Bristol-Myers Squibb (Celgene) | ✓ | ✓ | − | ✓ | ◐ | ✓ |
| Adaptimmune Therapeutics plc | ◐ | − | ◐ | ✓ | − | ◐ |
| Bluebird Bio Inc. | − | ◐ | ◐ | ◐ | ◐ | ◐ |
| Legend Biotech Corporation | − | ◐ | − | − | ✓ | − |
| Sangamo Therapeutics Inc. | − | ◐ | ◐ | ◐ | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Novartis AG82
2Gilead Sciences80
3Inc. (Kite Pharma)77
4Bristol-Myers Squibb (Celgene)75
5Adaptimmune Therapeutics plc65
6Bluebird Bio Inc.59
7Legend Biotech Corporation54
8Sangamo Therapeutics Inc.50
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Novartis AGGilead Sciences
Challenger2
Strong scale, closing on the leaders.
Inc. (Kite Pharma)Bristol-Myers Squibb (Celgene)
Contender2
Focused players with pockets of strength.
Adaptimmune Therapeutics plcBluebird Bio Inc.
Niche2
Specialists in a single segment or region.
Legend Biotech CorporationSangamo Therapeutics Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Therapy Type in North America, then scale across Personalized Cell Therapeutic Market — a $67M beachhead inside a $1.08B market.
Beachhead (SOM)$67Mobtainable near-term
Serviceable (SAM)$431Mreachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Chimeric Antigen Receptor T-cell (CAR-T) Therapy
Best fit — highest urgency & budget in Therapy Type.
Economic buyer77 fit
T-cell Receptor (TCR) Therapy
Strong fit — clear ROI and a fast path to value.
End user64 fit
Tumor-Infiltrating Lymphocytes (TIL) Therapy
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Therapy Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Cell Source & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Indication
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel28%
Digital / self-serve21%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Therapy Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Personalized Cell Therapeutic Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified24%
Evaluation14%
Closed-won6%
$19.1KCAC
$71KLTV
3.7:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Personalized Cell Therapeutic Market is a durable-growth opportunity — $8.99B by 2033, compounding at 8.8%.
TAM · 2025$4.58Btoday
TAM · 2033$8.99Bforecast
CAGR8.8%2027–2033
Cumulative$59.1Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$8.99BTotal addressable market
SAM$3.23BServiceable available market
SOM$654MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.8% CAGR
Demand compounds through 2033, outpacing GDP across Therapy Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Therapy Type moving from early to mainstream — durable secular demand.
Consolidation upside
17+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$8.99BLarge & growingTAM by 2033 at 8.8% CAGR
$3.23BServiceable nowreachable with today’s model
$654MBeachhead winobtainable near-term share
17+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$7.01BBear5.7% CAGR
$8.99BBase8.8% CAGR
$11.5BBull11.6% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Cell Source optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Personalized Cell Therapeutic Market — a $5.14B market by 2033. Plan: grow share from 8.3% to 12.7%.
Market size · 2033$5.14Btotal addressable
Market CAGR11.4%2027–2033
Target share12.7%from 8.3% today
Revenue ambition$653Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.3% | 12.7% | On track |
| Revenue | $439M | $653M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 36.8% | 41.8% | Behind |
| Customer retention | 90.9% | 92.6% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Therapy Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Cell Source capability
A defensible second engine — invest in Cell Source to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Therapy Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Cell Source
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $85M capacity & capability investment
- Greenlight bolt-on M&A in Cell Source
- Authorise North America expansion plan
- Fund R&D program for Therapy Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossBehind
- Input-cost & supply riskBehind
- Regulatory / policy changeAhead
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Personalized Cell Therapeutic Market conversation — a $10.1B market you can size, segment and defend in minutes.
Market size · 2033$10.1Btotal opportunity
Growth9.4%CAGR to 2033
Addressable buyers1,071+accounts in scope
Typical ROI7.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Therapy Type
Goal Grow share in Therapy Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.5×return on cost, year one
< 3 mopayback period
$63K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
17+players profiled in this market
Coverage includes
Novartis AGGilead SciencesInc. (Kite Pharma)Bristol-Myers Squibb (Celgene)Adaptimmune Therapeutics plcBluebird Bio Inc.Legend Biotech CorporationSangamo Therapeutics Inc.+9 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Personalized Cell Therapeutic Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Personalized Cell Therapeutic Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Personalized 3D Printed Orthotics Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportPersonalized 3D Printed Implant Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportPersonal Home Workout Software Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportPersonal Heart Rate Monitoring Device Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportPersonal Health Record Tools Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportPersonal Health Record Software Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportPersonal Health Management Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportPersonal Genome Services Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportPersonal Gene Sequencing Service Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportPersonal Fitness System Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportPersonal Fall Prevention Equipment Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportPersonal Exposure Monitoring Device Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.